Market Access News | pharmaphorum

News

J&J copay lawsuit against drug benefit firm gets green light

Johnson & Johnson has been cleared to continue a lawsuit filed last year against drug benefit programme SaveOnSP, which claims it defrauded a payment assistance programme for patients o

News

EU clears Enhertu for HER2-low breast cancer

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be

News

FDA advisors back Cidara antifungal rezafungin

An FDA advisory committee has recommended approval of Cidara Therapeutics' once-weekly antifungal therapy rezafungin, setting it up to become the first new option for severe infections caus

News

ALS drug tofersen will face FDA advisors, says Biogen

Biogen will have to make the case for its amyotrophic lateral sclerosis (ALS) therapy tofersen to an FDA advisory committee in March before it gets a decision on approval.

News

FDA blocks early nod for Lilly's Alzheimer's drug donanemab

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track

News

NICE backs Alnylam's Amvuttra for rare form of amyloidosis

Alnylam's gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available

J&J copay lawsuit against drug benefit firm gets green light

EU clears Enhertu for HER2-low breast cancer

FDA advisors back Cidara antifungal rezafungin

ALS drug tofersen will face FDA advisors, says Biogen

FDA blocks early nod for Lilly's Alzheimer's drug donanemab

NICE backs Alnylam's Amvuttra for rare form of amyloidosis

Simple blood test could aid in global TB fight

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks